Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

T cell large granular lymphocyte leukemia and chronic NK lymphocytosis.

Barilà G, Calabretto G, Teramo A, Vicenzetto C, Gasparini VR, Semenzato G, Zambello R.

Best Pract Res Clin Haematol. 2019 Sep;32(3):207-216. doi: 10.1016/j.beha.2019.06.006. Epub 2019 Jun 22. Review.

PMID:
31585621
2.

Identification of a miR-146b-FasL axis in the development of neutropenia in T large granular lymphocyte leukemia.

Mariotti B, Calabretto G, Rossato M, Teramo A, Castellucci M, Barilà G, Leoncin M, Vicenzetto C, Facco M, Semenzato G, Bazzoni F, Zambello R.

Haematologica. 2019 Aug 29. pii: haematol.2019.225060. doi: 10.3324/haematol.2019.225060. [Epub ahead of print]

3.

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S.

Haematologica. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657. [Epub ahead of print]

4.

Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma.

Carrino M, Quotti Tubi L, Fregnani A, Canovas Nunes S, Barilà G, Trentin L, Zambello R, Semenzato G, Manni S, Piazza F.

Cell Death Discov. 2019 May 21;5:98. doi: 10.1038/s41420-019-0179-1. eCollection 2019.

5.

Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study.

Barilà G, Compagno N, Liço A, Berno T, Bonaldi L, Teramo A, Manni S, Branca A, Frigo AC, Cinetto F, Piazza F, Semenzato G, Zambello R.

Br J Haematol. 2019 Aug;186(3):e13-e17. doi: 10.1111/bjh.15849. Epub 2019 Mar 10. No abstract available.

PMID:
30854624
6.

Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.

Zambello R, Crimì F, Lico A, Barilà G, Branca A, Guolo A, Varin C, Vezzaro R, Checuz L, Scapin V, Berno T, Pizzi M, Ponzoni A, De Biasi E, Vio S, Semenzato G, Zucchetta P, Lacognata C.

Ann Hematol. 2019 Mar;98(3):679-689. doi: 10.1007/s00277-018-3555-7. Epub 2018 Dec 11.

7.

Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.

Mian M, Pescosta N, Badiali S, Cappelletto PC, Marcheselli L, Luminari S, Patriarca F, Zambello R, Pascarella A, Tagariello G, Marabese A, Mondello P, Billio A, Cortelazzo S.

Br J Haematol. 2019 Jun;185(5):944-947. doi: 10.1111/bjh.15645. Epub 2018 Nov 26. No abstract available.

PMID:
30478966
8.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.

Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.

PMID:
29910180
9.

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation.

Barilà G, Teramo A, Calabretto G, Ercolin C, Boscaro E, Trimarco V, Carraro S, Leoncin M, Vicenzetto C, Cabrelle A, Facco M, Piazza F, Semenzato G, Zambello R.

Blood Cancer J. 2018 Jun 5;8(6):51. doi: 10.1038/s41408-018-0088-1. No abstract available.

10.

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.

Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L.

Qual Life Res. 2018 Jun;27(6):1545-1554. doi: 10.1007/s11136-018-1827-2. Epub 2018 Mar 8.

PMID:
29520559
11.

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.

Canovas Nunes S, Manzoni M, Pizzi M, Mandato E, Carrino M, Quotti Tubi L, Zambello R, Adami F, Visentin A, Barilà G, Trentin L, Manni S, Neri A, Semenzato G, Piazza F.

Blood Cancer J. 2018 Feb 13;8(2):20. doi: 10.1038/s41408-018-0053-z.

12.

STAT3 mutation impacts biological and clinical features of T-LGL leukemia.

Teramo A, Barilà G, Calabretto G, Ercolin C, Lamy T, Moignet A, Roussel M, Pastoret C, Leoncin M, Gattazzo C, Cabrelle A, Boscaro E, Teolato S, Pagnin E, Berno T, De March E, Facco M, Piazza F, Trentin L, Semenzato G, Zambello R.

Oncotarget. 2017 Jun 27;8(37):61876-61889. doi: 10.18632/oncotarget.18711. eCollection 2017 Sep 22.

13.

Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma.

Lacognata C, Crimì F, Guolo A, Varin C, De March E, Vio S, Ponzoni A, Barilà G, Lico A, Branca A, De Biasi E, Gherlinzoni F, Scapin V, Bissoli E, Berno T, Zambello R.

Clin Radiol. 2017 Oct;72(10):850-857. doi: 10.1016/j.crad.2017.05.004. Epub 2017 Jun 3.

PMID:
28587715
14.

IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy.

Campagnolo M, Zambello R, Nobile-Orazio E, Benedetti L, Marfia GA, Riva N, Castellani F, Bianco M, Salvalaggio A, Garnero M, Ruiz M, Mataluni G, Fazio R, Ermani M, Briani C.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1094-1097. doi: 10.1136/jnnp-2017-315736. Epub 2017 May 13. No abstract available.

PMID:
28501820
15.

Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.

Ferreri AJ, Sassone M, Zaja F, Re A, Spina M, Rocco AD, Fabbri A, Stelitano C, Frezzato M, Rusconi C, Zambello R, Couto S, Ren Y, Arcari A, Bertoldero G, Nonis A, Scarfò L, Calimeri T, Cecchetti C, Chiozzotto M, Govi S, Ponzoni M.

Lancet Haematol. 2017 Mar;4(3):e137-e146. doi: 10.1016/S2352-3026(17)30016-9. Epub 2017 Feb 17.

PMID:
28219694
16.

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.

Manni S, Carrino M, Manzoni M, Gianesin K, Nunes SC, Costacurta M, Tubi LQ, Macaccaro P, Taiana E, Cabrelle A, Barilà G, Martines A, Zambello R, Bonaldi L, Trentin L, Neri A, Semenzato G, Piazza F.

Oncotarget. 2017 Feb 28;8(9):14604-14619. doi: 10.18632/oncotarget.14654.

17.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U.

Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.

PMID:
27927586
18.

Pustular eruption associated with granulocyte colony-stimulating factor treatment.

Brumana MB, Russo I, Zambello R, Alaibac M.

G Ital Dermatol Venereol. 2018 Apr;153(2):276-277. doi: 10.23736/S0392-0488.16.05084-7. Epub 2016 Nov 15.

PMID:
27845511
19.

Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia.

Briani C, Visentin A, Cavallaro T, Cacciavillani M, Cabrini I, Ferrari S, Zambello R, Trentin L.

Ann Hematol. 2017 Jan;96(1):159-161. doi: 10.1007/s00277-016-2852-2. Epub 2016 Oct 19. No abstract available.

PMID:
27761605
20.

Steroid-responsive hyperammonemic encephalopathy as first manifestation of multiple myeloma.

Gaiani A, Pompanin S, Zambello R, Briani C, Cagnin A.

Neurol Sci. 2017 Mar;38(3):503-505. doi: 10.1007/s10072-016-2730-7. Epub 2016 Oct 7. No abstract available.

PMID:
27718015
21.

Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia.

Visentin A, Gurrieri C, Imbergamo S, Lessi F, Di Maggio SA, Frezzato F, Adami F, Zambello R, Piazza F, Semenzato G, Trentin L.

Hematol Oncol. 2017 Dec;35(4):925-928. doi: 10.1002/hon.2343. Epub 2016 Sep 19. No abstract available.

PMID:
27641225
22.

A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.

Laurenzana I, Caivano A, Trino S, De Luca L, La Rocca F, Simeon V, Tintori C, D'Alessio F, Teramo A, Zambello R, Traficante A, Maietti M, Semenzato G, Schenone S, Botta M, Musto P, Del Vecchio L.

Oncotarget. 2016 Oct 4;7(40):65171-65184. doi: 10.18632/oncotarget.11496.

23.

Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study.

Dalla Torre C, Zambello R, Cacciavillani M, Campagnolo M, Berno T, Salvalaggio A, De March E, Barilà G, Lico A, Lucchetta M, Ermani M, Briani C.

Neurology. 2016 Sep 13;87(11):1161-6. doi: 10.1212/WNL.0000000000003093. Epub 2016 Aug 17.

PMID:
27534712
24.

Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.

Quotti Tubi L, Canovas Nunes S, Brancalion A, Doriguzzi Breatta E, Manni S, Mandato E, Zaffino F, Macaccaro P, Carrino M, Gianesin K, Trentin L, Binotto G, Zambello R, Semenzato G, Gurrieri C, Piazza F.

Leukemia. 2017 Feb;31(2):292-300. doi: 10.1038/leu.2016.209. Epub 2016 Aug 1.

PMID:
27479180
25.

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.

Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S, Ghione P, Pitini V, Cuzzocrea S, Mian M.

Ann Hematol. 2016 Jun;95(7):1107-14. doi: 10.1007/s00277-016-2668-0. Epub 2016 Apr 22.

PMID:
27103007
26.

Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?

Mian M, Tinelli M, DE March E, Turri G, Meneghini V, Pescosta N, Berno T, Marabese A, Mondello P, Patriarca F, Pizzolo G, Semenzato G, Cortelazzo S, Zambello R.

Anticancer Res. 2016 Mar;36(3):1059-65.

PMID:
26976998
27.

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A.

Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. Epub 2016 Jan 4. Erratum in: Blood. 2018 Mar 29;131(13):1495.

28.

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V, Tani M, Marasca R, Cabras MG, Zambello R, Santagostino A, Ilariucci F, Carli G, Musto P, Savini P, Marino D, Ghio F, Gentile M, Cox MC, Vallisa D.

Leuk Lymphoma. 2016 Aug;57(8):1823-30. doi: 10.3109/10428194.2015.1106536. Epub 2015 Dec 15.

PMID:
26666433
29.

Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints.

Fiocco U, Martini V, Accordi B, Caso F, Costa L, Oliviero F, Scanu A, Felicetti M, Frallonardo P, Facco M, Boso D, Molena B, Zambello R, Ramonda R, Cozzi F, Scarpa R, Basso G, Semenzato G, Dayer JM, Doria A, Punzi L.

J Rheumatol Suppl. 2015 Nov;93:48-52. doi: 10.3899/jrheum.150636.

PMID:
26523057
30.

Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.

Trimarco V, Ave E, Facco M, Chiodin G, Frezzato F, Martini V, Gattazzo C, Lessi F, Giorgi CA, Visentin A, Castelli M, Severin F, Zambello R, Piazza F, Semenzato G, Trentin L.

Oncotarget. 2015 Dec 8;6(39):42130-49. doi: 10.18632/oncotarget.6239.

31.

Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy.

Visentin A, Compagno N, Cinetto F, Imbergamo S, Zambello R, Piazza F, Semenzato G, Trentin L, Agostini C.

Haematologica. 2015 Dec;100(12):e515-8. doi: 10.3324/haematol.2015.126763. Epub 2015 Aug 20. No abstract available.

32.

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, Tarella C, Di Nicola M, D'Arco AM, Doa G, Bruno-Ventre M, Assanelli A, Foppoli M, Citterio G, Fanni A, Mulè A, Caligaris-Cappio F, Ciceri F.

J Clin Oncol. 2015 Nov 20;33(33):3903-10. doi: 10.1200/JCO.2015.61.1236. Epub 2015 Aug 17.

PMID:
26282634
33.

Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia.

Visentin A, Facco M, Frezzato F, Castelli M, Trimarco V, Martini V, Gattazzo C, Severin F, Chiodin G, Martines A, Bonaldi L, Gianesello I, Pagnin E, Boscaro E, Piazza F, Zambello R, Semenzato G, Trentin L.

Clin Lymphoma Myeloma Leuk. 2015 Oct;15(10):612-20.e1-5. doi: 10.1016/j.clml.2015.06.001. Epub 2015 Jun 20.

PMID:
26233718
34.

Transcriptional network profile on synovial fluid T cells in psoriatic arthritis.

Fiocco U, Martini V, Accordi B, Caso F, Costa L, Oliviero F, Scanu A, Facco M, Boso D, Gatto M, Felicetti M, Frallonardo P, Ramonda R, Piva L, Zambello R, Agostini C, Scarpa R, Basso G, Semenzato G, Dayer JM, Punzi L, Doria A.

Clin Rheumatol. 2015 Sep;34(9):1571-80. doi: 10.1007/s10067-015-3002-2. Epub 2015 Jul 9.

PMID:
26152611
35.

Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation.

Zambello R, Bonaldi L, Berno T, Martines A, Sechettin E, De March E, Branca A, Lico A, Minotto C, Briani C, Gurrieri C, Temporin F, Battistutta C, Piazza F, Cavraro M, Trentin L, Semenzato G.

Clin Lymphoma Myeloma Leuk. 2015 Oct;15(10):592-8. doi: 10.1016/j.clml.2015.05.003. Epub 2015 Jun 6.

PMID:
26141212
36.

Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.

Mosna F, Papayannidis C, Martinelli G, Di Bona E, Bonalumi A, Tecchio C, Candoni A, Capelli D, Piccin A, Forghieri F, Bigazzi C, Visani G, Zambello R, Zanatta L, Volpato F, Paolini S, Testoni N, Gherlinzoni F, Gottardi M.

Am J Hematol. 2015 Jun;90(6):515-23. doi: 10.1002/ajh.24000. Epub 2015 Apr 1.

37.

Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.

Musto P, Fraticelli VL, Mansueto G, Madonna E, Nozza A, Andriani A, Mussetti A, Ballanti S, Bongarzoni V, Baraldi A, Patriarca F, Vincelli D, Falcone A, Derudas D, Califano C, Zambello R, Mele G, Fragasso A, Baldini L, Storti S.

Leuk Lymphoma. 2015 May;56(5):1510-3. doi: 10.3109/10428194.2014.982644. Epub 2015 Mar 3. No abstract available.

PMID:
25651428
38.

Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells.

Gattazzo C, Teramo A, Passeri F, De March E, Carraro S, Trimarco V, Frezzato F, Berno T, Barilà G, Martini V, Piazza F, Trentin L, Facco M, Semenzato G, Zambello R.

Haematologica. 2014 Dec;99(12):1826-33. doi: 10.3324/haematol.2014.105726. Epub 2014 Sep 5.

39.

Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients.

Poullot E, Zambello R, Leblanc F, Bareau B, De March E, Roussel M, Boulland ML, Houot R, Renault A, Fest T, Semenzato G, Loughran T, Lamy T.

Ann Oncol. 2014 Oct;25(10):2030-5. doi: 10.1093/annonc/mdu369. Epub 2014 Aug 5.

40.

Psoriasis induced by thalidomide in a patient with multiple myeloma.

Ferrazzi A, Zambello R, Russo I, Alaibac M.

BMJ Case Rep. 2014 Jun 27;2014. pii: bcr2014204469. doi: 10.1136/bcr-2014-204469.

41.

Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2.

Manni S, Toscani D, Mandato E, Brancalion A, Quotti Tubi L, Macaccaro P, Cabrelle A, Adami F, Zambello R, Gurrieri C, Semenzato G, Giuliani N, Piazza F.

Leukemia. 2014 Oct;28(10):2094-7. doi: 10.1038/leu.2014.178. Epub 2014 Jun 4. No abstract available.

PMID:
24897506
42.

Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?

Zambello R, Teramo A, Gattazzo C, Semenzato G.

Transl Med UniSa. 2014 Feb 4;8:4-11. eCollection 2014 Jan.

43.

Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?

Zambello R, Teramo A, Barilà G, Gattazzo C, Semenzato G.

Front Immunol. 2014 Feb 26;5:72. doi: 10.3389/fimmu.2014.00072. eCollection 2014. Review.

44.

Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole.

Frezzato F, Trimarco V, Martini V, Gattazzo C, Ave E, Visentin A, Cabrelle A, Olivieri V, Zambello R, Facco M, Zonta F, Cristiani A, Brunati AM, Moro S, Semenzato G, Trentin L.

Br J Haematol. 2014 Jun;165(5):659-72. doi: 10.1111/bjh.12815. Epub 2014 Mar 7.

PMID:
24606526
45.

Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia.

Gattazzo C, Martini V, Frezzato F, Trimarco V, Tibaldi E, Castelli M, Facco M, Zonta F, Brunati AM, Zambello R, Semenzato G, Trentin L.

Haematologica. 2014 Jun;99(6):1069-77. doi: 10.3324/haematol.2013.090183. Epub 2014 Feb 14.

46.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M.

J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

PMID:
24449241
47.

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.

Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, Bertorelle R, Manni S, Pavan L, Lessi F, Zambello R, Trentin L, Adami F, Ruzzene M, Pinna LA, Semenzato G, Piazza F.

J Hematol Oncol. 2013 Oct 12;6:78. doi: 10.1186/1756-8722-6-78.

48.

Cyclophosphamide as a first-line therapy in LGL leukemia.

Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T.

Leukemia. 2014 May;28(5):1134-6. doi: 10.1038/leu.2013.359. Epub 2013 Nov 27. No abstract available.

49.

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.

Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M.

Am J Hematol. 2014 Apr;89(4):355-62. doi: 10.1002/ajh.23641. Epub 2014 Feb 5.

50.

Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A, Pizzi M, Cappellesso R, Zaffino F, Di Maggio SA, Cabrelle A, Marino F, Zambello R, Trentin L, Adami F, Gurrieri C, Semenzato G, Piazza F.

PLoS One. 2013 Sep 27;8(9):e75280. doi: 10.1371/journal.pone.0075280. eCollection 2013.

Supplemental Content

Loading ...
Support Center